[
    [
        {
            "time": "",
            "original_text": "药明康德(02359.HK)：资本公积储备转增股本，共增发4.19亿股A股及4871.82万H股",
            "features": {
                "keywords": [
                    "药明康德",
                    "资本公积",
                    "转增股本",
                    "增发",
                    "A股",
                    "H股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德(02359.HK)：资本公积储备转增股本，共增发4.19亿股A股及4871.82万H股",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业: 注册申请高增长, 审评通过高效率, 国产创新药迎来黄金收获期",
            "features": {
                "keywords": [
                    "医药生物",
                    "注册申请",
                    "审评通过",
                    "国产创新药",
                    "黄金收获期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业: 注册申请高增长, 审评通过高效率, 国产创新药迎来黄金收获期",
                "Correlation": 6,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]